West-Ward Pharmaceuticals Corp has received FDA approval for Ondansetron Hydrochloride Intramuscular Injection (ANDA 076780), strengthening the company's portfolio within the motion sickness and chemotherapy-induced nausea market by providing a more affordable therapeutic option. This authorization is expected to increase accessibility for the acute anti-emetic treatment, likely driving market share as hospitals seek cost-effective alternatives to branded formulations.